Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000176227 | SCV000227844 | benign | not specified | 2015-05-15 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000176227 | SCV000313664 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Gene |
RCV000176227 | SCV000523800 | benign | not specified | 2016-03-07 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Invitae | RCV000459547 | SCV000563647 | benign | Developmental and epileptic encephalopathy, 14; Autosomal dominant nocturnal frontal lobe epilepsy 5 | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002314617 | SCV000847422 | likely benign | Inborn genetic diseases | 2016-03-21 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Athena Diagnostics Inc | RCV000176227 | SCV001476653 | benign | not specified | 2019-12-17 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002269943 | SCV002555479 | benign | Developmental and epileptic encephalopathy, 14 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002269944 | SCV002555480 | benign | Autosomal dominant nocturnal frontal lobe epilepsy 5 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001701778 | SCV004158982 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | KCNT1: BP4, BP7, BS1, BS2 |
Genome Diagnostics Laboratory, |
RCV001701778 | SCV001927927 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001701778 | SCV001963878 | likely benign | not provided | no assertion criteria provided | clinical testing |